Inhibiting IL-8 interactions with CXCR1/2 has been shown to have a therapeutic benefit in clinical trials in combination with enzalutamide in treatment-resistant PCa (Expanded in Section 5.4) [59]. This evidence concerns the gene CXCL8 and posterior cortical atrophy.